To hear about similar clinical trials, please enter your email below
Trial Title:
RC48-ADC in Breast Cancer
NCT ID:
NCT05851677
Condition:
Breast Cancer
Conditions: Official terms:
Breast Neoplasms
Disitamab vedotin
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Other
Intervention:
Intervention type:
Drug
Intervention name:
Disitamab vedotin
Description:
recommended but not required regimen of 2.0mg/kg, iv, day1, every 2 weeks
Arm group label:
RC48-ADC
Other name:
RC48-ADC
Summary:
To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with
breast cancer.
Criteria for eligibility:
Study pop:
breast cancer patients with prior or current use of Disitamab vedotin (RC48-ADC)
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Histologically confirmed breast cancer;
- Prior or current use of Disitamab vedotin (RC48-ADC);
Exclusion Criteria:
- Participating in clinical trials involving Disitamab vedotin (RC48-ADC) or not.
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Address:
City:
Shanghai
Zip:
200127
Country:
China
Status:
Recruiting
Contact:
Last name:
Wenjin Yin
Phone:
86(21)68385569
Email:
yinwenjin@renji.com
Start date:
June 1, 2023
Completion date:
August 2027
Lead sponsor:
Agency:
RenJi Hospital
Agency class:
Other
Source:
RenJi Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05851677
